IFCT-1805 ELDERLY Phase III randomized trial of atezolizumab in elderly patients with advanced Non-Small-Cell Lung Cancer and receiving monthly carboplatin with weekly paclitaxel chemotherapy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515946-17-00

Acronym

IFCT-1805

Enrollment

500

Registered

2024-12-11

Start date

2019-07-22

Completion date

Unknown

Last updated

2025-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Small Cell Lung Cancer

Brief summary

Overall survival

Detailed description

Progression-free survival, Best overall response rate, Duration of response

Interventions

DRUGTecentriq 1 200 mg concentrate for solution for infusion

DRUGPACLITAXEL

DRUGCARBOPLATIN

Eligibility

Sex/Gender

All

Age

65 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Secondary

Measure	Time frame
Progression-free survival, Best overall response rate, Duration of response	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026